CRISPR Therapeutics AG (CRSP) vs Veradermics Incorporated (MANE)

CRISPR Therapeutics AG and Veradermics Incorporated are both Biotechnology companies. Veradermics Incorporated is the larger, with a market value of $5.4B against $4.7B — 1.1× the size. Veradermics Incorporated has the higher net margin (0.00% vs −1,812.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Veradermics Incorporated leads on 8 and CRISPR Therapeutics AG on 4.

Valuation

Metric CRSP MANE Biotechnology median
P/E n/m n/m 10.60
P/S 191.85 n/m 9.40
P/B 2.93 6.87 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 124.89 n/m 9.02
Earnings yield (9.50%) (33.20%) (32.88%)
Free cash flow yield (7.80%) (2.20%) (23.13%)

Profitability

Metric CRSP MANE Biotechnology median
Gross margin 100.00% — 68.51%
Operating margin (2,114.75%) 0.00% 0.00%
Net margin (1,812.07%) 0.00% 0.00%
Free cash flow margin (1,496.56%) 0.00% 0.00%
Return on equity (25.60%) 0.00% (51.96%)
Return on assets (19.00%) (20.86%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CRSP MANE Biotechnology median
Revenue growth (TTM) (34.34%) — 6.76%
EPS growth (last fiscal year) (49.08%) (211.38%) 29.88%
Revenue growth, 5-year CAGR 37.31% — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric CRSP MANE Biotechnology median
Debt to equity 0.36 0.00 0.00
Current ratio 16.21 70.53 4.97
Net debt to EBITDA 3.06 1.96 1.01

Dividend

Metric CRSP MANE Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CRSP MANE Biotechnology median
Market cap 4.71b 5.37b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack